Safety Analyses of the Phase 3 VISION Trial of [
(177)Lu-PSMA-617
Metastatic castration-resistant prostate cancer
Radioligand therapy
Treatment exposure
Treatment-emergent adverse events
Journal
European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
24
03
2023
revised:
30
11
2023
accepted:
11
12
2023
medline:
18
3
2024
pubmed:
8
1
2024
entrez:
7
1
2024
Statut:
ppublish
Résumé
[ VISION was an international, open-label study. Patients were randomised 2:1 to receive The any-grade TEAE incidence was similar in cycles 1-4 and cycles 5-6. TEAE frequency was similar across all cycles of Longer exposure to For patients with metastatic prostate cancer no longer responding to hormone therapy, an increase in the number of cycles of treatment with a radioactive compound called
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
[
METHODS
METHODS
VISION was an international, open-label study. Patients were randomised 2:1 to receive
KEY FINDINGS AND LIMITATIONS
UNASSIGNED
The any-grade TEAE incidence was similar in cycles 1-4 and cycles 5-6. TEAE frequency was similar across all cycles of
CONCLUSIONS AND CLINICAL IMPLICATIONS
CONCLUSIONS
Longer exposure to
PATIENT SUMMARY
RESULTS
For patients with metastatic prostate cancer no longer responding to hormone therapy, an increase in the number of cycles of treatment with a radioactive compound called
Identifiants
pubmed: 38185538
pii: S0302-2838(23)03297-9
doi: 10.1016/j.eururo.2023.12.004
pii:
doi:
Substances chimiques
Dipeptides
0
Heterocyclic Compounds, 1-Ring
0
Lutetium
5H0DOZ21UJ
Prostate-Specific Antigen
EC 3.4.21.77
PSMA-617
0
Radiopharmaceuticals
0
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
382-391Informations de copyright
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.